Skip to main content
Soufyan Annakib on Muck Rack

Soufyan Annakib

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Soufyan

Contact Soufyan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients

|
By Soufyan Annakib, CHU Nîmes, Emma Di Méglio, Yona Dibert-Bekoy
| Wiley Online Library Verified
1 Background Pembrolizumab is an anti-Programmed cell Death protein-1 (anti-PD1) approved in second-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) [1]. As with other immune checkpoint inhibitors (ICI), the side effects of pembrolizumab are referred to as immune-related side effects. They can quickly worsen and lead to more medical complications [2, 3].
Open in Who Shared Issue with article?

Quality of Life with Monoclonal Antibody Therapies for Locally Advanced or Metastatic Urothelial Carcinoma: A Systematic Review

|
By Frédéric Fiteni, Nadine Houédé, Soufyan Annakib
| ncbi.nlm.nih.gov
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Open in Who Shared View Duplicates (614) Issue with article?
See all 2 articles